$BLUE
bluebird bio, Inc.

2014 Q3 Form 10-Q Financial Statement

#000156459015009649 Filed on November 05, 2015

View on sec.gov

Income Statement

Concept 2014 Q3
Revenue $6.365M
YoY Change -0.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.600M
YoY Change 73.68%
% of Gross Profit
Research & Development $16.65M
YoY Change 91.24%
% of Gross Profit
Depreciation & Amortization $1.540M
YoY Change 396.77%
% of Gross Profit
Operating Expenses $16.65M
YoY Change 91.24%
Operating Profit -$17.01M
YoY Change 176.27%
Interest Expense -$100.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$20.00K
YoY Change -145.45%
Pretax Income -$17.03M
YoY Change 178.59%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$17.03M
YoY Change 178.59%
Net Earnings / Revenue -267.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$605.0K
COMMON SHARES
Basic Shares Outstanding 28.60M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $215.4M
YoY Change -0.65%
Cash & Equivalents $89.60M
Short-Term Investments $125.8M
Other Short-Term Assets $7.900M
YoY Change 68.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $223.3M
YoY Change 0.84%
LONG-TERM ASSETS
Property, Plant & Equipment $14.98M
YoY Change 177.78%
Goodwill $13.13M
YoY Change
Intangibles $29.16M
YoY Change
Long-Term Investments $48.40M
YoY Change
Other Assets $1.162M
YoY Change -17.0%
Total Long-Term Assets $106.9M
YoY Change 1472.82%
TOTAL ASSETS
Total Short-Term Assets $223.3M
Total Long-Term Assets $106.9M
Total Assets $330.2M
YoY Change 44.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.641M
YoY Change 218.27%
Accrued Expenses $9.700M
YoY Change 94.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.52M
YoY Change 22.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $323.0K
YoY Change -99.17%
Total Long-Term Liabilities $323.0K
YoY Change -99.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.52M
Total Long-Term Liabilities $323.0K
Total Liabilities $68.30M
YoY Change -3.2%
SHAREHOLDERS EQUITY
Retained Earnings -$127.8M
YoY Change 41.11%
Common Stock $287.0K
YoY Change 21.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $261.9M
YoY Change
Total Liabilities & Shareholders Equity $330.2M
YoY Change 44.66%

Cashflow Statement

Concept 2014 Q3
OPERATING ACTIVITIES
Net Income -$17.03M
YoY Change 178.59%
Depreciation, Depletion And Amortization $1.540M
YoY Change 396.77%
Cash From Operating Activities -$20.77M
YoY Change 134.42%
INVESTING ACTIVITIES
Capital Expenditures -$1.770M
YoY Change -16.11%
Acquisitions
YoY Change
Other Investing Activities -$173.8M
YoY Change -173920.0%
Cash From Investing Activities -$175.6M
YoY Change 8635.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.2M
YoY Change -9442.37%
NET CHANGE
Cash From Operating Activities -20.77M
Cash From Investing Activities -175.6M
Cash From Financing Activities 110.2M
Net Change In Cash -86.11M
YoY Change 614.61%
FREE CASH FLOW
Cash From Operating Activities -$20.77M
Capital Expenditures -$1.770M
Free Cash Flow -$19.00M
YoY Change 181.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
300000
CY2015Q3 blue Construction Financing Obligation
ConstructionFinancingObligation
43777000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.52
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33979000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25593000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
121000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29239000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40962000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1913000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28115000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
630000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11797000
us-gaap Net Income Loss
NetIncomeLoss
-119508000
us-gaap Net Income Loss
NetIncomeLoss
-29165000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
blue Noncash Benefit On Release Of Income Tax Valuation Allowance
NoncashBenefitOnReleaseOfIncomeTaxValuationAllowance
11797000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36384000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.18
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2015000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
78000
us-gaap Other Noncash Expense
OtherNoncashExpense
528000
us-gaap Other Noncash Expense
OtherNoncashExpense
246000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2717000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-166000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
623000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2604000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5320000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5613000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12643000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-19005000
blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-640000
blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
2124000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-65344000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44029000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
8816000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-209000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3618000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6303000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4673000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
470499000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
174021000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
132239000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-184788000
blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
109766000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2375000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
112141000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-116676000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89603000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
43759000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
12768000
blue Noncash Or Part Noncash Acquisition Noncash Financial Equity Issued
NoncashOrPartNoncashAcquisitionNoncashFinancialEquityIssued
19348000
blue Construction Financing Obligation Non Cash
ConstructionFinancingObligationNonCash
43777000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1475000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1298000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
24000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
223000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company develops, manufactures and intends to market therapies to safely and effectively deliver genes useful in the treatment of severe genetic and rare diseases and in the field of T cell-based immunotherapy. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, the Company sold 2,941,176 shares of common stock through an underwritten public offering at a price of $170.00 per share. The aggregate net proceeds received by the Company from the offering were $477.2 million, net of underwriting discounts and commissions and offering expenses of approximately $22.8 million.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.33%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates are used in the following areas, among others: fair value estimates used to assess potential impairment of long-lived assets, construction financing lease obligations, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes. Actual results could materially differ from those estimates.&nbsp;&nbsp;</p></div>
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2941176
CY2015Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
477200000
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
170.00
CY2015Q2 us-gaap Investment Banking Advisory Brokerage And Underwriting Fees And Commissions
InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
22800000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
484151000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
144229000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
133000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
83000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
77000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
484201000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
144158000
CY2015Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
901711000
CY2015Q3 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
8336000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
492003000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
6796000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
197000000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
134400000
CY2015Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2014Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2015Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3496000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
67420000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19141000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5856000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3401000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5358000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4943000
CY2015Q3 blue Accrued Goods And Services
AccruedGoodsAndServices
13034000
CY2014Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
7358000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-06
CY2013Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9900
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2013Q2 blue Rent Abatement Credits
RentAbatementCredits
200000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
29500000
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
7800000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013Q2 blue Letter Of Credit Related With New Lease Agreement
LetterOfCreditRelatedWithNewLeaseAgreement
1300000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
1300000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7757000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1188000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1124000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
55000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3661000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1090000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3552000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
115.69
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
43.05
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.83
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.47
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
37.87
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
8500000
CY2015Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
CY2015Q3 blue Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
200000
blue Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
200000
CY2015Q3 blue Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
0
blue Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
0

Files In Submission

Name View Source Status
0001564590-15-009649-index-headers.html Edgar Link pending
0001564590-15-009649-index.html Edgar Link pending
0001564590-15-009649.txt Edgar Link pending
0001564590-15-009649-xbrl.zip Edgar Link pending
blue-10q_20150930.htm Edgar Link pending
blue-20150930.xml Edgar Link completed
blue-20150930.xsd Edgar Link pending
blue-20150930_cal.xml Edgar Link unprocessable
blue-20150930_def.xml Edgar Link unprocessable
blue-20150930_lab.xml Edgar Link unprocessable
blue-20150930_pre.xml Edgar Link unprocessable
blue-ex1030_164.htm Edgar Link pending
blue-ex311_9.htm Edgar Link pending
blue-ex312_7.htm Edgar Link pending
blue-ex321_11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201511051903338581451.jpg Edgar Link pending
g201511051903415771452.jpg Edgar Link pending
g201511051903427021453.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending